During the third quarter, Allspring Global Investments Holdings LLC increased its position in Halozyme Therapeutics by 247.8%, acquiring an additional 20,033 shares to bring its total to 28,117 shares valued at approximately 2.11 million. Other major institutional moves included DLD Asset Management LP establishing a new stake valued at 650.25 million in the second quarter, Arrowstreet Capital Limited Partnership boosting its holding by 127.8% to 2.54 million shares (132.19 million), and Los Angeles Capital Management LLC expanding its position by 951.8% to 973,670 shares (50.65 million). Qube Research & Technologies Ltd and Norges Bank also initiated new positions worth 51.30 million and 45.03 million respectively, bringing institutional ownership to 97.79% of the outstanding shares.

In early January, Director Bernadette Connaughton sold 2,000 shares at an average of 70.25, realizing 140,500, which reduced her stake by 4.75% to 40,123 shares. Earlier, on December 1, CEO Helen Torley sold 16,569 shares at an average of 68.92, generating 1.14 million and trimming her holding by 2.28% to 708,719 shares. Over the last 90 days, insiders disposed of 45,661 shares totaling 3.14 million, representing 2.40% insider ownership.

Eight research firms maintain a buy rating, six issue holds and one issues a sell rating, yielding an average consensus rating of Hold and an average price target of 76.45. Notable changes include Zacks Research downgrading to Hold in early October, Morgan Stanley reducing its target from 80 to 79 while retaining an Overweight stance, Weiss Ratings upgrading to Buy (b-) at year-end, Leerink Partners moving to Market Perform with a 70 target, and JPMorgan increasing its objective from 63 to 65 with a Neutral rating.

In the latest quarter, Halozyme reported earnings per share of 1.72, exceeding consensus by 0.09 and up from 1.27 a year earlier. Revenue rose 22.1% year-over-year to 354.26 million versus expectations of 339.18 million. The company achieved a net margin of 47.91% and a return on equity of 156.95%. Current ratio stands at 1.59, quick ratio at 1.37 and debt-to-equity at 1.59, while 50-day and 200-day moving averages are 68.13 and 66.46 respectively. Sell-side forecasts project full-year EPS of 4.73.